scholarly journals Leukocyte and Skeletal Muscle Telomere Length and Body Composition in Monozygotic Twin Pairs Discordant for Long-term Hormone Replacement Therapy

2017 ◽  
Vol 20 (2) ◽  
pp. 119-131 ◽  
Author(s):  
Elina Sillanpää ◽  
Paula Niskala ◽  
Eija K. Laakkonen ◽  
Elodie Ponsot ◽  
Markku Alén ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Body Composition ◽  
Hormone Replacement Therapy ◽  
Telomere Length ◽  
Hormone Replacement ◽  
Monozygotic Twin ◽  
Fat Free Mass ◽  
Thigh Muscle ◽  
Muscle Area

Estrogen-based hormone replacement therapy (HRT) may be associated with deceleration of cellular aging. We investigated whether long-term HRT has effects on leukocyte (LTL) or mean and minimum skeletal muscle telomere length (SMTL) in a design that controls for genotype and childhood environment. Associations between telomeres, body composition, and physical performance were also examined. Eleven monozygotic twin pairs (age 57.6 ± 1.8 years) discordant for HRT were studied. Mean duration of HRT use was 7.3 ± 3.7 years in the user sister, while their co-twins had never used HRT. LTL was measured by qPCR and SMTLs by southern blot. Body and muscle composition were estimated by bioimpedance and computed tomography, respectively. Physical performance was measured by jumping height and grip strength. HRT users and non-users did not differ in LTL or mean or minimum SMTL. Within-pair correlations were high in LTL (r= 0.69,p= .020) and in mean (r= 0.74,p= .014) and minimum SMTL (r= 0.88,p= .001). Body composition and performance were better in users than non-users. In analyses of individuals, LTL was associated with BMI (r2= 0.30,p= .030), percentage total body (r2= 0.43,p= .014), and thigh (r2= 0.55,p= .004) fat, while minimum SMTL was associated with fat-free mass (r2= 0.27,p= .020) and thigh muscle area (r2= 0.42,p= .016). We found no associations between HRT use and telomere length. Longer LTLs were associated with lower total and regional fat, while longer minimum SMTLs were associated with higher fat-free mass and greater thigh muscle area. This suggests that telomeres measured from different tissues may have different associations with measures of body composition.

Changes in body composition at menopause—age, lifestyle or hormone deficiency?

2002 ◽  
Vol 8 (4) ◽  
pp. 137-140 ◽  
Author(s):  
Morten B Sørensen
Keyword(s):  
Weight Loss ◽  
Body Composition ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Good Reason ◽  
Health Benefit ◽  
Lifestyle Changes ◽  
Hormone Deficiency

One of the major concerns of perimenopausal women is obesity—and for a good reason. Both general and abdominal obesity as well as loss of skeletal muscle (sarcopenia) are accelerated through the menopausal transition and lifestyle changes as well as sex hormone deficiency play important roles. Most well conducted clinical trials have demonstrated hormone replacement therapy induced reversal or at least impairment of menopausal changes in body composition and the common worry that it causes weight gain is unsubstantiated. Coaching of weight loss in obese individuals is often a frustrating task but is nevertheless of immense importance because of the health hazards of obesity. Through the climacteric period, short-term hormone replacement therapy, with or without androgens for preservation of muscle mass, might inhibit obesity and this is likely to boost motivation for introduction of more comprehensive and long-lasting initiatives linked to persistent weight loss and long-term health benefit.

Enhanced Rate of Resting Energy Expenditure in Women Using Hormone-Replacement Therapy: Preliminary Results

2008 ◽  
Vol 16 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Mylène Aubertin-Leheudre ◽  
Eric D.B. Goulet ◽  
Isabelle J. Dionne
Keyword(s):  
Body Composition ◽  
Hormone Replacement Therapy ◽  
Energy Expenditure ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Resting Energy Expenditure ◽  
Long Term Treatment ◽  
Resting Energy

Hormone-replacement therapy (HRT) attenuates the menopause-associated alterations in body composition. It is not known, however, whether this effect is a result of a concomitant increase in energy expenditure. The authors examined whether women submitted to a long-term HRT treatment presented greater energy expenditure than women who had never used HRT. We compared 13 postmenopausal women using HRT (>1 yr) with 13 age- (±2 yr) and body-mass-index-matched (BMI; ±1.5kg/m2) postmenopausal women not using HRT. Resting energy expenditure (REE; indirect calorimetry), body composition, and daily (DEE) and physical activity (PAEE) energy expenditure (accelerometry) were obtained. Although BMI, fat mass, fat-free mass, DEE, and PAEE were similar between groups, the HRT group displayed a significantly greater REE than the no-HRT group (Δ +222 kcal/day). In conclusion, the authors observed that a long-term treatment with HRT is associated with a greater REE in postmenopausal women. These results need to be confirmed.

Evaluation of the Body Composition and Fat Distribution in Long-Term Users of Hormone Replacement Therapy

1999 ◽  
Vol 48 (1) ◽  
pp. 52-55 ◽  
Author(s):  
G. Perrone ◽  
Y. Liu ◽  
O. Capri ◽  
C. Critelli ◽  
F. Barillaro ◽  
...  
Keyword(s):  
Body Composition ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Fat Distribution ◽  
The Body

scholarly journals Hormone replacement therapy enhances IGF-1 signaling in skeletal muscle by diminishing miR-182 and miR-223 expressions: a study on postmenopausal monozygotic twin pairs

Aging Cell ◽  
2014 ◽  
Vol 13 (5) ◽  
pp. 850-861 ◽  
Author(s):  
Fabiola Olivieri ◽  
Maarit Ahtiainen ◽  
Raffaella Lazzarini ◽  
Eija Pöllänen ◽  
Miriam Capri ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Monozygotic Twin

scholarly journals Effects of Recombinant Human Growth Hormone for 1 Year on Body Composition and Muscle Strength in Children on Long-Term Steroid Therapy: Randomized Controlled, Delayed-Start Study

2013 ◽  
Vol 98 (7) ◽  
pp. 2746-2754 ◽  
Author(s):  
Dominique Simon ◽  
Corinne Alberti ◽  
Marianne Alison ◽  
Loïc Le Henaff ◽  
Didier Chevenne ◽  
...  
Keyword(s):  
Body Composition ◽  
Muscle Strength ◽  
Recombinant Human Growth Hormone ◽  
Composite Index ◽  
Human Growth ◽  
Thigh Muscle ◽  
Muscle Area ◽  
Rhgh Therapy ◽  
Randomized Controlled

Context: Recombinant human GH (rhGH) improves growth and body composition in glucocorticoid-treated children. Its effects on muscle strength are poorly evaluated. Objectives: Our objective was to evaluate rhGH effects on muscle strength in children receiving long-term glucocorticoid therapy; effects on height SD score (SDS) and body composition were assessed also. Design and Setting: A randomized, controlled, delayed-start study of rhGH for 12 months was started after randomization (baseline) or 6 months later (M6). Patients: Patients included 30 children with various diagnoses. Intervention: rhGH was administered at 0.065 mg/kg/d for 6 months and then in the dosage maintaining serum IGF-I levels below +2 SDS for chronological age. Main Outcome Measures: The primary criterion was the between-group difference in composite index of muscle strength (CIMS) change at M6. Secondary criteria included between-group differences in CIMS SDSheight, lean mass (LM), thigh muscle area (MA), and height SDS changes at M6; these parameters were also assessed in the overall population after 1 year of rhGH therapy. Results: At M6, rhGH therapy did not significantly affect changes in CIMS or CIMS SDSheight (+17.6% vs +7.5% and +0.14 ± 0.38 vs +0.11 ± 0.62, respectively); the rhGH-treated group had significantly larger changes in height SDS (+0.2 [0.3] vs −0.2 [0.3]; P = 0.003), LM (+7.3% [+3.7%; +21.6%] vs 0% [−4.7%; +3.2%]; P = 0.002), and MA (+8.8% [+5%; +15.6%] vs. −0.6% [−6.3%; +7.7%]; P = 0.01) compared with the untreated group. After 1 year of rhGH, height SDS, LM, and MA increased significantly, CIMS increased by 24.7% (+5.8%; +34.2%), and CIMS SDSheight remained within the normal range. Conclusions: rhGH increased height, LM, and MA. However, muscle strength did not improve significantly.

scholarly journals Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs

2009 ◽  
Vol 107 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Paula H. A. Ronkainen ◽  
Vuokko Kovanen ◽  
Markku Alén ◽  
Eija Pöllänen ◽  
Eeva-Maija Palonen ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Muscle Power ◽  
Hormone Replacement ◽  
Thigh Muscle ◽  
Sectional Area ◽  
Cross Sectional ◽  
Muscle Composition ◽  
Muscle Cross Sectional Area

We investigated whether long-term hormone replacement therapy (HRT) is associated with mobility and lower limb muscle performance and composition in postmenopausal women. Fifteen 54- to 62-yr-old monozygotic female twin pairs discordant for HRT were recruited from the Finnish Twin Cohort. Habitual (HWS) and maximal (MWS) walking speeds over 10 m, thigh muscle composition, lower body muscle power assessed as vertical jumping height, and maximal isometric hand grip and knee extension strengths were measured. Intrapair differences (IPD%) with 95% confidence intervals (CI) were calculated. The mean duration of HRT use was 6.9 ± 4.1 yr. MWS was on average 7% (0.9 to 13.1%, P = 0.019) and muscle power 16% (−0.8 to 32.8%, P = 0.023) greater in HRT users than in their cotwins. Thigh muscle cross-sectional area tended to be larger (IPD% = 6%, 95% CI: −0.07 to 12.1%, P = 0.065), relative muscle area greater (IPD% = 8%, CI: 0.8 to 15.0%, P = 0.047), and relative fat area smaller (IPD% = −5%, CI: −11.3 to 1.2%, P = 0.047) in HRT users than in their sisters. There were no significant differences in maximal isometric strengths or HWS between users and nonusers. Subgroup analyses revealed that estrogen-containing therapies (11 pairs) significantly decreased total body and thigh fat content, whereas tibolone (4 pairs) tended to increase muscle cross-sectional area. This study showed that long-term HRT was associated with better mobility, greater muscle power, and favorable body and muscle composition among 54- to 62-yr-old women. The results indicate that HRT is a potential agent in preventing muscle weakness and mobility limitation in older women.

Long term hormone replacement therapy (HT) does not affect post-menopausal total body composition

2015 ◽  
Vol 104 (3) ◽  
pp. e5-e6
Author(s):  
A.H. Bayer ◽  
K.N. Goldman ◽  
R. Mauricio ◽  
M.J. Nachtigall ◽  
F. Naftolin ◽  
...  
Keyword(s):  
Body Composition ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Total Body Composition ◽  
Total Body ◽  
Post Menopausal

scholarly journals Body Composition by CT vs. DXA: Long-Term Prediction of Mortality in the Health Health ABC Cohort

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 239-239
Author(s):  
Samaneh Farsijani ◽  
Lingshu Xue ◽  
Robert Boudreau ◽  
Adam Santanasto ◽  
Stephen Kritchevsky ◽  
...  
Keyword(s):  
Body Composition ◽  
Fat Mass ◽  
Mortality Risk ◽  
Subcutaneous Fat ◽  
Thigh Muscle ◽  
Muscle Area ◽  
Muscle Density ◽  
Long Term Follow Up

Abstract Background: Early work in the Health ABC cohort found that strength, but not muscle size predicted mortality. Recent literature suggests that body composition by computerized tomography (CT) and magnetic resonance imaging (MRI) predicts adverse health outcomes in diverse populations, but has not been directly compared to dual-energy X-ray absorptiometry (DXA) for predicting mortality. Objective: With long term follow-up, we reexamined body composition and mortality in Health ABC, comparing DXA and CT measures of muscle and fat. Methods: The Health ABC study assessed body composition in 2911 older adults (age 73.6±2.9 years) in 1996-97. Mid-thigh CTs were read for muscle area, inter-muscular, subcutaneous-fat areas and muscle density (HU). DXAs were read for whole body fat mass and appendicular lean mass (ALM). Mortality was assessed every 6-months through 2014 (maximum 17.4 years). Cox proportional hazards models, adjusting for age, sex, race, height, weight, physical activity, smoking and comorbidities were used to assess mortality risk. Results: Strong correlations were observed between mid-thigh muscle and subcutaneous fat areas by CT and leg lean and fat mass by DXA (P<0.05). Lower mortality rates, per SD, were associated with higher CT muscle area (HR-men=0.76 [95%CI: 0.68-0.86]; HR-women=0.84 [0.75-0.94]), muscle density (HR-men=0.86 [0.79-0.93]; HR-women=0.89 [0.81-0.97]) and higher subcutaneous-fat (HR-men=0.90 [0.81-0.99]; HR-women=0.87 [0.77-0.98]), adjusting for covariates. Similarly for DXA, greater ALM (HR-men=0.56 [0.44-0.71]; HR-women=0.77 [0.59-1.01]) and higher total fat mass (HR-men=0.53 [0.40-0.72]; HR-women=0.58 [0.37-0.90]) were associated with lower risk of death. Conclusion: With long term follow-up, both CT and DXA assessments of body composition predicted all-cause mortality risk.

Sign in / Sign up

Export Citation Format

Share Document